Transcatheter Aortic Valve Replacement
for Severe Aortic Stenosis in a Transplanted Heart
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Introduction

Case Description

Heart transplantation has become the definitive
treatment for end stage heart failure. As the longterm survival of heart transplant recipients
improves, the incidence of post-transplant valvular
heart disease is increasing. Tricuspid regurgitation
is the most common valvular heart disease
following transplant, while left-sided valvular
disease is less frequent. Transcatheter aortic valve
replacement (TAVR) has become an alternative to
surgical aortic valve replacement in high-risk
patients with severe aortic stenosis (AS).

A 54-year-old patient with history of orthotopic heart
transplantation (HTx) 25 years prior for ischemic
cardiomyopathy as well as kidney transplantation
twice (30 years and 9 years prior) was admitted to
the hospital with decompensated heart failure. Mild
AS was first noted 3 years prior. An updated
echocardiogram revealed severe calcific AS with a
valve area of 0.8 cm2. Aortic valve (AV) peak
velocity was 4.6 m/s, with a mean gradient of 53
mmHg. Pre-TAVR cardiac computed tomography
was avoided as the patient had chronic kidney
disease stage 4 in a transplanted kidney. Instead, a
preoperative transesophageal echocardiogram was
utilized for valve sizing. The patient underwent
transfemoral TAVR with a successful placement of a
29 mm Evolut PRO + valve. A month after the
procedure, echocardiography revealed AV mean
gradient of 10 mmHg and AV area of 1.9 cm2 with
trivial paravalvular regurgitation.
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Discussion

Long-term survival of heart transplant recipients
has significantly improved. As a result, the
incidence of valvular heart diseases post-HTx is
growing. This leads to the need for re-intervention
in a group of patients with high surgical risk. Our
patient had extreme surgical risk based on the
Society of Thoracic Surgeons Predicted Risk of
Mortality which was prohibitive of surgery. There
are no data regarding TAVR versus surgery in HTx
recipients. However, TAVR seems to represent a
safe and effective therapeutic option for aortic
valve disease in high-risk or inoperable heart
transplant recipients. Our patient was the first case
of successful transfemoral TAVR performed in our
hospital 25 years after HTx.

Conclusion
Aortic valve stenosis is rare following cardiac
transplantation. However, with improving longterm survival rates after transplant, AS may be
seen with increasing frequency in the future. Our
case demonstrates that TAVR is an effective and
safe alternative in managing severe AS in a
transplanted
heart,
even
decades
after
transplantation.
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Figure 1. TTE showing severe calcific aortic stenosis with
restricted opening during end systole, aortic valve area 0.8
cm2.
Figure 2. Still view of aortic root angiogram showing patent
coronary system prior to full deployment of TAVR valve.
Figure 3.TTE, Status post TAVR with 29 mm EVOLUT
PRO+, showing optimal depth implantation and wide-open
aortic valve in end systole.
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